Trial Update

Monday, 04 June 2012 Posted in News, 2012

In exciting developments, three patients have now joined the PAN 1 study. The PAN 1 study aim is to prospectively evaluate hENT1 as a predictive biomarker of benefit from gemcitabine treatment in advanced Pancreatic Cancer. In lay English, this means researchers at the AGITG will test whether hENT1 can show whether an individual patient with advanced Pancreatic Cancer will get benefit from the standard Pancreatic Cancer chemotherapy drug Gemcitabine or not.

 

$2M Milestone Reached

Thursday, 01 March 2012 Posted in News, 2012

Thanks to all our wonderful supporters we have reached $2m dollars in donations!! It is a significant milestone in our young life and worth stopping for a moment and savouring such an achievement.

 

Pancreatic Cancer in the News

Wednesday, 29 February 2012 Posted in News, 2012

An interesting article appeared in the press recently reporting that "CANCER research spending in Australia is fragmented and wasteful and has failed to tackle the deadliest forms of the disease, say representatives of charities and government funding bodies who want an overhaul of the $300 million sector."